This is a StreetInsider.com Premium Only Page

Relmada Therapeutics (RLMD) –

Apr 9, 2024 04:15 PM Form DEFA14A RELMADA THERAPEUTICS,

Apr 9, 2024 04:11 PM Form DEF 14A RELMADA THERAPEUTICS, For: May 24

Mar 19, 2024 04:24 PM Relmada Therapeutics (RLMD) Misses Q4 EPS by 1c

Mar 19, 2024 04:15 PM Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 19, 2024 04:11 PM Form 8-K RELMADA THERAPEUTICS, For: Mar 19

Mar 19, 2024 04:06 PM Form 10-K RELMADA THERAPEUTICS, For: Dec 31

Mar 12, 2024 07:30 AM Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024

Mar 5, 2024 07:30 AM Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Feb 20, 2024 05:56 PM Form 144 RELMADA THERAPEUTICS, Filed by: O'Gorman Cedric

Feb 14, 2024 08:54 AM Form SC 13G/A RELMADA THERAPEUTICS, Filed by: Deep Track Capital, LP

Feb 14, 2024 07:50 AM Form SC 13G/A RELMADA THERAPEUTICS, Filed by: RTW INVESTMENTS, LP

Feb 13, 2024 05:19 PM Form SC 13G/A RELMADA THERAPEUTICS, Filed by: VANGUARD GROUP INC

Jan 31, 2024 06:30 PM Form 4 RELMADA THERAPEUTICS, For: Jan 29 Filed by: TRAVERSA SERGIO

Jan 31, 2024 06:29 PM Form 4 RELMADA THERAPEUTICS, For: Jan 29 Filed by: Shenouda Maged

Jan 31, 2024 06:28 PM Form 4 RELMADA THERAPEUTICS, For: Jan 29 Filed by: Ence Chuck

Jan 11, 2024 04:31 PM Form 8-K RELMADA THERAPEUTICS, For: Jan 05

Jan 4, 2024 08:11 AM Form 8-K RELMADA THERAPEUTICS, For: Jan 04

Jan 4, 2024 07:33 AM Relmada Therapeutics (RLMD) Provides Corporate Update

Jan 4, 2024 07:30 AM Relmada Therapeutics Provides Corporate Update

Jan 3, 2024 05:01 PM Form 8-K RELMADA THERAPEUTICS, For: Jan 03

Dec 19, 2023 05:29 PM Form 4 RELMADA THERAPEUTICS, For: Dec 15 Filed by: TRAVERSA SERGIO

Dec 19, 2023 05:29 PM Form 4 RELMADA THERAPEUTICS, For: Dec 15 Filed by: Shenouda Maged

Dec 19, 2023 05:28 PM Form 4 RELMADA THERAPEUTICS, For: Dec 15 Filed by: Kelly Paul Edward

Dec 19, 2023 05:28 PM Form 4 RELMADA THERAPEUTICS, For: Dec 15 Filed by: Fedeli Fabiana

Dec 19, 2023 05:28 PM Form 4 RELMADA THERAPEUTICS, For: Dec 15 Filed by: GLASSPOOL JOHN

Dec 19, 2023 05:27 PM Form 4 RELMADA THERAPEUTICS, For: Dec 15 Filed by: CASAMENTO CHARLES J

Dec 19, 2023 05:27 PM Form 4 RELMADA THERAPEUTICS, For: Dec 15 Filed by: Ence Chuck

Nov 8, 2023 04:30 PM Relmada Therapeutics (RLMD) Tops Q3 EPS by 18c

Nov 8, 2023 04:30 PM Relmada Therapeutics (RLMD) Tops Q3 EPS by 18c

Nov 8, 2023 04:06 PM Form 10-Q RELMADA THERAPEUTICS, For: Sep 30

Nov 8, 2023 04:02 PM Form 8-K RELMADA THERAPEUTICS, For: Nov 08

Nov 8, 2023 04:01 PM Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 3, 2023 07:30 AM Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023

Oct 11, 2023 09:01 AM Form 8-K RELMADA THERAPEUTICS, For: Oct 11

Oct 11, 2023 08:31 AM Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023

Oct 10, 2023 05:19 PM Form 8-K RELMADA THERAPEUTICS, For: Oct 10

Oct 9, 2023 07:30 AM Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

Oct 6, 2023 07:30 AM Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress

Oct 4, 2023 08:54 AM Form 8-K RELMADA THERAPEUTICS, For: Oct 04

Sep 20, 2023 04:48 PM Form 8-K RELMADA THERAPEUTICS, For: Sep 20

Sep 20, 2023 08:31 AM Relmada Therapeutics (RLMD) Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder

Sep 20, 2023 08:30 AM Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder

Sep 6, 2023 09:23 AM Form 8-K RELMADA THERAPEUTICS, For: Sep 05

Aug 23, 2023 07:30 AM Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder

Aug 11, 2023 09:00 PM Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm

Aug 10, 2023 04:55 PM Form 8-K RELMADA THERAPEUTICS, For: Aug 10

Aug 10, 2023 06:39 AM Relmada Therapeutics Inc (RLMD) PT Lowered to $25 at Mizuho Securities

Aug 8, 2023 04:52 PM Relmada Therapeutics (RLMD) Tops Q2 EPS by 6c

Aug 8, 2023 04:30 PM Form 8-K RELMADA THERAPEUTICS, For: Aug 08

Aug 8, 2023 04:02 PM Form 10-Q RELMADA THERAPEUTICS, For: Jun 30